Introduction
============

Lung cancer is the most common cause of cancer death for both men and women worldwide [@B1]. Generally, the majority of cancer deaths are caused by metastasis rather than by the primary tumor itself [@B2]. The development of an oncogenic state is a complex process involving the accumulation of multiple independent mutations, which lead to deregulation of cell signaling pathways on controlling cell growth and cell fate [@B3]. The sequential and rate-limiting steps of metastasis involve lots of gene expression, regulations, and interactions [@B4].

Lung adenocarcinoma (LAD), a histological subtype of non-small cell lung cancer (NSCLC), has increased incidence over the past several decade years from 20% of lung cancer cases to nearly 40%, followed with a high mortality [@B5]. Based on the 2004 World Health Organization Pathologic Criteria, the LADs have four major individual subtypes (acinar, papillary, bronchioloalveolar carcinoma, and solid carcinoma with mucus formation) [@B6]. The acinar pattern is characterized by acini and tubules composed of cuboidal or columnar cells which may be mucin producing and resemble bronchial gland or bronchial lining epithelial cells. The papillary pattern shows papillae with secondary and tertiary papillary structures that replace the underlying lung architecture. Solid adenocarcinoma with mucin is composed of sheets polygonal cells lacking acini, tubules, and papillae but with mucin. Bronchioloalveolar carcinoma (BAC) pattern shows growth of neoplastic cells along pre-existing alveolar structures without evidence of stromal, vascular, or pleural invasion [@B7]. However, most of the cases are histologically heterogeneous and consist of more than one subtype. The most frequent subtype was the adenocarcinomas mixed subtype, representing approximately 80% of resected adenocarcinomas [@B6].

The most powerful method for NSCLC patients prognosis and treatment guiding is the tumor-node-metastasis (TNM) staging system [@B8]. Based on the tumor size (T), local invasion, and presence of nodal (N) and distant metastases (M), patients are categorized into seven stages (IA, IB, IIA, IIB, IIIA, IIIB and IV) [@B9]. Early stage detection of NSCLC helps to choose a proper treatment for patients. Usually, surgical resection is the first option for early stage subjects, and is considered curative in patients with stage I lung cancer [@B10]. Recently, multiple clinical trials have demonstrated that adjuvant chemotherapy significantly improved the survival of the patients in stage IB-IIIA[@B11]. The Lung Adjuvant Cisplatin Evaluation (LACE), which was based on a pooled meta-analysis of five largest randomized trials, has demonstrated that cisplatin-based adjuvant chemotherapy improved survival in patients with completely resected NSCLC especially in stages II and III, but may have no benefit for patients with stage IA and only a marginal benefit for patients with stage IB [@B12]. However, the Japan Lung Cancer Research Group conducted adjuvant trials with uracil-tegafur, showing a survival benefit with adjuvant chemotherapy in stage IB LADs [@B13]. These results suggested that molecular mechanisms occurring in stage IB might be different from Stage IA.

Multiple studies have demonstrated the ability of signature genes, which derived from microarray expression profiles, to define cancer subtypes, recurrence of disease and response to specific therapies [@B14]. Several assays showed that the signature of stage I NSCLC alone could not reveal differences in outcome in patients with stage II disease, which indicated that existence of additional molecular mechanisms in more advanced lung carcinomas [@B15],[@B16],[@B17]. The various signal transduction pathways in LAD of different stages might help to find out the pivotal events in the tumor development.

DNA microarray technology provides a sufficient screening tool for searching differentially expressed genes (DEGs) by investigating the gene expression profile [@B18]. However, many microarray-based studies showed that some results were not reproducible [@B19]. It commonly resulted from improper analysis and insufficient control of false positives, and was often exacerbated by the small sample sizes [@B20]. Meta-analysis is an efficient, indispensable and inexpensive supplementary tool for the microarray data analysis. It uses statistical techniques to combine results from independent but related studies. Integrated information from multiple studies can improve the reliability and generalizability of the combined results, and the enhanced statistical power favored a more precise estimate of DEGs. The method of meta-analysis was gradually improved to achieve different research goals, such as robustifying cross-platform classification, and identifying overlaps from heterogeneous datasets of different cancers and tissues [@B21]. With the increasing number of available free public microarray datasets, meta-analysis of multiple datasets has been widely used and proved to be a useful method in searching DEGs [@B22].

Various studies had used microarray gene expression profiles to analyze oncogenic pathway [@B3]. Several molecular pathways involved in NSCLC malignancy have been revealed, such as Epidermal Growth Factor Receptor pathway (EGFR) and Bcl-2 pathway [@B23]. However, few studies focused on changes on the pathway level in cancer development. Most LADs are consist of more than one subtype [@B6]. In order to find the common features of these subtypes on pathway level, we performed the meta-analysis of the LAD microarray data to analyze the progression-associated genes and pathways in tumor development by stage comparison rather than survival signature analysis. Four LAD datasets was included in our analysis to search significantly regulated genes and pathways in comparisons between normal lung tissues and LADs of different stages, which was based on the TNM stage classification. Real-time PCR experiment was applied to verify the expression of genes in different LAD cell lines.

Material and Method
===================

Meta-analysis
-------------

### Data collection

Data used in this study were publicly available from cDNA and oligo (Affymetrix) microarrays experiments on LADs. Studies were eligible if they fulfilled all the following criteria: every single dataset must contain at least one stage with ≥3 of tumor samples, as well as at least ≥3 of normal tissues; stage information would be available for tumor samples. The raw data (CEL files) of oligo microarray and the normalized data of cDNA microarray were downloaded from the website. The tumor adjacent normal tissues were defined as normal tissue.

Four datasets, encompassing 353 patients, were eligible for our meta-analysis (Table [1](#T1){ref-type="table"}). Dataset1 and dataset3 were downloaded from <http://www.broad.mit.edu/cgi-bin/cancer/datasets.cgi> [@B28] and <http://caarraydb.nci.nih.gov/caarray/publicExperimentDetailAction.do?expId=1015897558050283> [@B29], respectively. Both dataset2 (GSE3398, [@B30]) and dataset4 (GSE10072, [@B31]) were downloaded from NCBI (<http://www.ncbi.nlm.nih.gov/>). Dataset 2 contained fewer samples than other datasets.

### Data processing

All the CEL files, which recorded the raw fluorescence intensity of the oligo microarrays, were preprocessed with the Robust Multichip Average (RMA) algorithm to normalize the data and generate more precise intensities for each probe. The calculation was performed with R language software and \'affy\' program package from Bioconductor (<http://www.bioconductor.org/>). For cDNA microarray, the normalized data were applied directly in the following analysis and missing data were allowed. We transformed the diverse identifier of each gene from the different datasets into one form-ref sequence ID using program from <http://genome-www5.stanford.edu/cgi-bin/source/sourceBatchSearch>. The average value was calculated if a gene appeared more than once in a single dataset.

### Data analysis

We performed the meta-analysis referred to Rhodes et al.\'s method [@B24]. The significance assessment was based on two null hypotheses that no genes were up-regulated or no genes were down-regulated in LADs. Firstly, we performed 10 000 one-sided random permutation t tests for every single dataset between normal samples (group 1) and tumor samples (group 2, such as stage IA). For an individual gene, a t statistic (t) was calculated and compared with 10 000 t statistics generated by randomly assigning the samples, and each gene obtained a study-specific P(t) in every single dataset. P(t)s equaled to zero were set to 0.0001. Secondly, the overlapping genes from the different datasets combinations were selected and the relevant summary statistic (S) was calculated with the P(t)s from preceding random permutation t tests for each gene, based on Fisher\'s method for combining P values [@B25]. These actual S statistics then compared to 1 000 000 S statistics generated by randomly selecting a P(t) from each dataset. Finally, to control the false discovery rate (FDR), the genes were sorted by the P(s) values and a new statistic Q was calculated according to Benjamini and Hochberg\' method [@B26] (Figure [1](#F1){ref-type="fig"}).

A designated gene might not exist in all eligible datasets, the meta-analysis of each comparison (e.g. Normal vs stage IA, Normal vs stage IB, etc.) (Figure [2](#F2){ref-type="fig"}) was performed in different dataset combinations (every two datasets, every three datasets etc.) to retain information as much as possible (Figure [1](#F1){ref-type="fig"}). Consequently, each gene might obtain several Q values and only the smallest Q value was used for the following analysis. All the calculation was implemented with perl software.

### Pathway and GO analysis

All the genes were imported into the pathway and GO analysis of the Genmapp software, which was downloaded from the web (<http://www.genmapp.org/> version 2.1, Hs-std 20070817). Genes with Q\<0.1 in the up-regulation or down-regulation groups were considered to be changed significantly. The remaining was considered as background genes. The associated pathways and GO were sorted by the Z score. The pathway was excluded if the number of hits ≤3. The pathway and GO with Z score \>1.96 was considered to be significant in the Genmapp result.

Experiments
-----------

### Cell culture

Lung adenocarcinoma cell lines (Calu-3 and H1299) and lung normal fibroblast cell line (WI-38) were obtained from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Calu-3 cells were grown in Eagle\'s Minimum Essential Medium (Invitrogen, Carlsbad, CA, USA), H1299 cells were grown in RPMI-1640 Medium (4.5g/L glucose) (Invitrogen), and WI-38 cell were grown in Eagle\'s Minimum Essential Medium, respectively. All the Medium were supplemented with 10% fetal bovine serum (Clarkbio, Seabrook, MD, USA) and antibiotics (100U/ml penicillin, 100 μg/ml streptomycin)(Invitrogen) and the cells were placed in a humidified atmosphere of 5% CO~2~ at 37 °C.

### Real-time PCR

The total RNA of Calu-3, H1299 and WI-38 cells were extracted using Trizol reagent (Invitrogen) and the cDNA was synthesized with superscript III reverse transcription PCR kit (Invitrogen). Quantitative real-time PCR was performed in 7900HT Fast Real-time PCR System (Applied Biosystems, Foster, CA, USA) with 2X HotSybr PCR Reaction Mix (NuStar Laboratory, San Francisco, CA, USA). In order to avoid DNA contamination, all the oligo nucleotide primers were designed to target to different exons of the selected genes except for *18SrRNA*, which has one single exon. The gene symbols and primers sequences of the amplified genes were shown in Table [2](#T2){ref-type="table"}. The *18SrRNA* and *GAPDH* were used as the endogenous controls. All PCR reactions were carried out with the following program: 2 min at 55 °C, 10 min at 95°C, and 40 cycles of 15s at 95°C and 1min at 60°C. After the amplification, the melting curve analysis was performed and the threshold cycles (Ct) was determined by the software SDS 2.3 (Applied Biosystems). The fold change of gene expression in WI-38 cells relative to Calu-3 or H1299 cells was calculated using 2^-⊿⊿CT^ method [@B27].

Results
=======

Common gene expression changes in different stages
--------------------------------------------------

Totally, four datasets, encompassing 353 patients, were eligible for our meta-analysis (Table [1](#T1){ref-type="table"}). Different combinations of datasets had different sets of overlapping genes, so we performed the meta-analysis for each possible combination (Figure [1](#F1){ref-type="fig"}). Genes with a Q\<0.1 which significantly changed in mRNA expression level in different comparisons were defined as DEGs. We counted the number of significant Qs for each gene. Thus, a significant gene had at least one significant Q value. The overall Q value and the frequencies of the significant Qs were informative to evaluate the reliability of the result. We performed six comparisons between normal tissues and LADs in different stages (Figure [2](#F2){ref-type="fig"}). The comparison between normal and stage IV revealed no DEGs. In total, the expression of 1 838 DEGs were found in the six different comparisons ([Additional file 1](#SM1){ref-type="supplementary-material"}: Supplementary Table 1A and 1B), and 918 genes were up-regulated and 920 genes were down-regulated at least once.

The datasets, sample numbers, and number of DEGs in different comparisons were listed in Table [3](#T3){ref-type="table"}. More DEGs might be obtained from more datasets combinations. Both Normal vs IIA and Normal vs IIB had 2 datasets, but more DEGs were found in the comparison of Normal vs IIB. After examining the samples of every stage, we found that stage IIA had fewer samples (4 samples in dataset1 and 3 samples in dataset4) than that of stage IIB (17 samples in dataset 1 and 18 samples in dataset 4). The comparison Normal vs IIIB included only 9 stage IIIB LAD samples from 3 datasets. Although fewer datasets was included in the comparison of Normal vs IIB, more DEGs (718) were found compared with that of Normal vs IIIB (321). Thus, smaller sample size might lead to fewer DEGs.

Many well-known metastasis-associated genes were found, such as *ERBB2*, *PLAU* and *MMP9* [@B28],[@B29],[@B30]. Interestingly, some gene family members had similar regulation tendency. As shown in Table [4](#T4){ref-type="table"}, eight genes (e.g. *IL6R*, *IL4R* and *IL7R*) of interleukin receptor family, thirteen genes (e.g. *COL13A1*and *COL1A1*) of collagen family, eight genes (e.g. *ITGB4* and *ITGAV*) of integrin family, eight genes (e.g. *MMP9* and *MMP13*) of metalloproteinase family, thirteen genes of histone cluster, five genes of minichromosome maintenance (MCM) complex component families, and four genes of inhibitor of DNA binding (Id) family were significantly changed in the mRNA expression level compared with normal tissues. Those gene families had been shown to be involved in cancer progression. The high proliferation state of cancer cells is associated with an increased expression of MCM proteins that can be detected in both malignant precursor lesions and carcinomas [@B31]. As the synthesis of histones is tightly coupled with DNA replication during S-phase of the cell cycle, histone mRNA level is often a proliferative marker in cancers [@B32],[@B33]. The overexpression of ITGAV had been found in several types of tumors to promote the invasion or be related with metastasis and late-stage [@B34],[@B35]. The expression of β4 increases significantly during malignant progression in squamous carcinomas of multiple tissues, including head and neck, skin, cervix, and lung [@B36]. Type IV collagen is a major component in most basement membranes. During the process of stromal invasion of lung adenocarcinoma, type IV collagen of alveolar basement membrane is remodelled from the complete type, composed of 1(IV)/2(IV)/3(IV)/4(IV)/5(IV) chains, to the incomplete type, composed of only 1(IV)/2(IV) chains[@B37]. In our study, the expression levels of COL4A3 and COL4A5 (corresponding to the type IV collagen 3/4 chains) were down-regulated in the LADs.

Intriguingly, we found that most of the genes from the same gene family were up-regulated (or down-regulated). The similar trend of expression of these gene family members suggested coordinate regulation. Binding sites for ETS or AP-1 transcription factors are found in the promoters of MMP family and these transcription factors have been reported to regulate MMP gene expression [@B38]. Besides, several members of *S100*, *HOX*, *CLDN*, *FOX*, *CDK* family were among the DEGs. Genes with unknown functions in LAD development were also found.

Pathways and GO in different stages
-----------------------------------

We performed pathways and GO categories analyses from the six comparisons separately using the Genmapp software. The pathways and GOs with Z score \> 1.96 were considered significant and ranked by their appearing times in the six comparisons ([Additional file 1](#SM1){ref-type="supplementary-material"}: Supplementary Table 2 and Table 3). Table [5](#T5){ref-type="table"} showed the top ten GO categories of the Genmapp result. Most of them were involved in the cancer development, plasma membrane and co-receptor/soluble ligand activity. Table [6](#T6){ref-type="table"} showed the top twenty-six pathways, which were significant in at least four comparisons, with rank value equal to 0 or 2.

Besides the well-known cancer-related pathways, the Adipogenesis, Circadian exercise, and Id pathway are important pathways revealed by our analysis. White adipose tissues could synthesize and secrete adipokines, which played important roles in inflammation, angiogenesis, lipid metabolism, cell proliferation, apoptosis, and cell differentiation [@B39]. The adipogenesis pathway had not been reported to be a significantly regulated pathway (SRP) in LAD before. Our result indicated it might play important roles in the development of LAD. Circadian clock genes were involved in cell proliferation, apoptosis, cell cycle control, and DNA damage, and many of them were silenced in cancer cells [@B40],[@B41],[@B42],[@B43],[@B44]. Id pathway included four important inhibitor of differentiation/DNA binding (ID) family members, *ID1*,*ID2*,*ID3*and*ID4*, which had been reported to be critical in cell differentiation and proliferation [@B45].

Validation of common cancer genes by real-time PCR
--------------------------------------------------

Normal lung fibroblast cell line WI-38 and two LAD cell lines Calu-3 and H1299 were used for qRT-PCR gene expression validation. Calu-3 had medium tumorigenicity but no metastasis characteristic, while H1299 had high tumorigenic and metastasis capacity. The genes in group A (Table [2](#T2){ref-type="table"}) were tested by WI-38 and Calu-3 cell lines. They were randomly selected from the DEGs from comparisons of Normal vs IA and Normal vs IB, but did not significantly changed in mRNA expression level in comparisons of Normal vs IIIA and Normal vs IIIB; the genes in group B were verified with WI-38 and H1299 cell lines. They were DEGs (Q\<0.05) randomly selected from the comparisons of Normal vs IIIA and Normal vs IIIB.

It was important to notice that in our meta-analysis, housekeeping genes *GAPDH* and *HPRT1* were overexpressed in LAD compared to normal tissues. The result was in consistent with Nguewa et al.\'s study, in which they found the *GAPDH* and *HPRT1* were not good internal control genes in lung tissue specimens, but the two genes could be used as internal controls when lung cell lines were applied for the experiment [@B46]. Our qRT-PCR assay demonstrated that the expression level of *GAPDH* was stable in the three different lung cell lines. Thus, we used both *GAPDH* and *18SrRNA*as internal controls. The genes with log 2 ratios ≥1 or ≤−1 were determined as significantly changed (overexpressed or underexpressed). As shown in Figure [3](#F3){ref-type="fig"}, if we considered the significant changes in expression level, the two methods (meta-analysis and real-time PCR) showed 77% consistency in group A and 66% in group B; If we considered the expression tendency, the two methods had matched over 90%. *SPP1* showed the opposite regulation tendency (Figure [3](#F3){ref-type="fig"}B). However, a homozygous partial deletion of p53 protein was existed in H1299 cell line, which might result in the down-regulation of *SPP1*, a target of p53 and was down-regulated when p53 was silenced [@B47]. Similar result was obtained when used *18SrRNA* as internal control (data not shown). Our analysis suggested a possible relationship between these genes and LAD metastasis.

Sample size, DEGs and pathways
------------------------------

Table [3](#T3){ref-type="table"} showed that small sample size in the comparison would lead to fewer DEGs. To investigate the effects of sample size, we compared the Q values of meta-analysis combining only two datasets for the 18 genes tested with real-time PCR. The results in Figure [4](#F4){ref-type="fig"} showed that the Q values from meta-analyses combining Dataset2, the one had the smallest sample size, always showed higher Q value than those analyses combined without Dataset2. Thus, meta-analysis integrating small sample size dataset led to fewer DEGs, as well as false negative.

The pathway calculation in Genmapp was influenced by the number of DEGs and total genes. Since we imported the same total genes in the six comparisons, the calculation of significantly regulated pathways (SRPs) were mainly determined by the DEGs. More DEGs would result in more SRPs (Table [3](#T3){ref-type="table"}). The comparison Normal vs IIA revealed only 4 SRPs which might arise from fewer DEGs. Thus, we only compared the SRPs in other five comparisons.

Interestingly, if comparison Normal vs IIA was deleted in the pathway analysis, we found that Oxidative Stress, Glycolysis/Gluconeogenesis and Integrin-mediated cell adhesion pathways were not significant in the comparison of Normal vs IA, but were significant (Z\>1.96) in other four comparisons.

Many types of cancer cell had increased levels of reactive oxygen species (ROS), which could cause DNA damage and might trigger tumor initiation, and the ROS-induced oxidative stress could contribute to tumor development not only through genetic, but also through epigenetic mechanisms [@B48],[@B49]. In our analysis, two important anti-oxidant genes in Oxidative Stress pathway exhibit varied expression between Stage IA and others. The ECSOD (SOD3), a mainly extracellular superoxide dismutase, was not a DEG in normal vs stage IA, while GCLC, which catalyses the initial rate limiting step of GSH synthesis, was significantly overexpressed in stage IB, IIB, IIIA and IIIB compared with normal tissues, other than in stage IA.

Most tumor cells displayed high rates of glycolysis, which could provide more nutrition and energy for the proliferation [@B50]. The LDHA, an important gene in Glycolysis/Gluconeogenesis pathway, was significantly overexpressed in stage IB, IIB and IIIA, but not in stage IA, compared with normal tissues. Integrin-mediated cell adhesion pathway, which mediated interaction between the tumor cell and the matrix, was closely associated with metastasis [@B51]. In our study, integrin alpha V (ITGAV) was significantly up-regulated in stage IB and IIB, but not in stage IA.

Discussion
==========

The development of lung cancer was a complex and gradual process. In this study, we combined four LAD gene expression studies based on Affymetrix and cDNA microarray platforms, to find LAD progression-associated genes and pathways using meta-analysis strategy. The increased sample size was intended to control false positives and increase statistical power in detecting important DEGs.

Different stages of LAD were compared with lung normal tissues to preserve information on the progress of metastasis. GO analysis indicated that many genes were involved in carcinogenesis and metastasis process-related categories, such as cell migration (*CEACAM1*, *CXCL12*, *CTGF*), cell proliferation (*HDGF*, *MDK*), cell motility (*SPP1*), cell adhesion (*CDH1*), and angiogenesis (*ANGPT1*). There were several well-known cancer-related pathways were found, which included TGF-beta, Focal adhesion, EGFR, Fas, TNF-alpha-NF-kB, MAPK, p38 MAPK, Wnt, Matrix Metalloproteinases (MMP), Integrin-mediated cell adhesion and IL pathways[@B52]. Some of them played significant roles in the progress of many kinds of tumors. Specially, the focal adhesion, MMP, integrin-mediated cell adhesion, and regulation of Actin Cytoskeleton pathways were closely related to metastasis, which mediated interaction between the tumor cell and the matrix [@B28],[@B29],[@B51],[@B53].

Adipogenesis, Circadian exercise, and Id pathway are important pathways revealed by our analysis. Typical functions of white adipose tissue were triglycerol storage and energy utilization. Recent studies indicated that white adipose tissue is a multi- functional endocrine organ that synthesizes and secretes adipokines (cytokine-like proteins). Many adipokines have a pivotal role in inflammation, angiogenesis, lipid metabolism, cell proliferation, apoptosis, and cell differentiation [@B39]. On the other hand, inducers derived from cancer cells significantly induced or enhanced adipogenesis [@B54]. Specially, it has recently been shown that *MMP11* is induced in adipose tissue by cancer cells as they invade their surrounding environment [@B55]. Additionally, *MMP2* and *MMP9*, which had been proved to take important effect on metastasis, were also produced and secreted by adipocytes in the adipose differentiate [@B28],[@B56].

There is growing evidence that many cellular clock genes were silenced in cancer cells[@B41]. Loss and dysregulation of *PER1* and *PER2*, two important circadian rhythm genes, have been found in many types of human cancers [@B40],[@B41],[@B42],[@B43],[@B44]. *PER1*was found to be silenced in 70% NSCLC patients [@B57]. *ID1*,*ID2*,*ID3*and*ID4* in Id pathway had been reported to be critical in cell differentiation and proliferation [@B45]. Only in the last two years, the *ID* genes had been reported in the small cell lung cancer (*ID1*,*ID2*,*ID3*and*ID4*) and NSCLC (*ID2*) [@B58],[@B59].

In addition, pathways involved in metabolism were revealed to be associated with LAD progress in our study. Prostaglandin, a ubiquitous hormone in human body, could stimulate human lung carcinoma cell growth, and the critical genes in prostaglandin synthesis had been proved to be associated with carcinogenesis [@B60],[@B61],[@B62]. The statin (a cholesterol-lowering agent) pathway functioned in the cholesterol metabolism and circulation had been found to be related to cancer development [@B63],[@B64],[@B65],[@B66]. Meanwhile, the metabolism of amino acid, nucleotide and other materials might also be accelerated during the process of metastasis. We identified a group of genes, which might associate with the complicated metastasis process in LAD. These genes were involved in a wide pathway network. They provided more information, and supplemented the well-known cancer-associated pathways.

The additional molecular mechanisms might exist in more advanced lung carcinomas such as stage II [@B15],[@B16],[@B17]. However, no comparison of the potential molecular mechanisms had been made among different stages of LAD. In our study, Oxidative stress, Glycolysis/Gluconeogenesis and Integrin-mediated cell adhesion pathways were showed to be significant in stages other than IA.

There were evidences that compared with normal counterparts, many types of cancer cell had increased levels of reactive oxygen species (ROS) [@B48],[@B49]. Mori et al.\'s study demonstrated that the invasive potential could be induced under long-term oxidative stress in mammary epithelial [@B67]. This antioxidant enzyme in Oxidative stress pathway was the major determinant in decreasing extracellular oxidant stress and might have fundamental effects on the extracellular redox state of lung tumors with potential consequences on tumor behavior [@B68]. Increased intracellular ROS (lipid peroxidation) and superoxide production were related with down-regulated ECSOD in NSCLC [@B69]. Several studies suggested that cells with active c-Myc may survive the ROS stress by up-regulating glutathione (GSH) synthesis, an important antioxidant in Oxidative stress pathway to minimize the oxidative damage [@B70]. GCLC catalyses the initial rate limiting step of GSH synthesis. Ray et al.\'s assay demonstrated that the up-regulation of GCLC mRNA in lung cancer cell lines (H292) could be induced by ROS [@B71].

Despite in the presence of a high O~2~ concentration, the glycolysis was enhanced in tumor cells, and provided more nutrition and energy for the proliferation [@B50]. Most tumor cells displayed high rates of glycolysis, aerobic or anaerobic, and many glycolytic tumor cells were also found to be aggressive [@B72]. Wu et al.\'s study demonstrated that A549 cells displayed a dependency on glycolysis and significantly up-regulated this pathway when their respiration was inhibited [@B73]. The *LDHA* is an important member in Glycolysis/Gluconeogenesis pathway. It could convert pyruvate, the product of glycolysis, into lactate and created an acidic environment to promote the invasion of cancer cells [@B74].

Integrin-mediated cell adhesion pathway was closely associated with cell proliferation, maintenance, mobility and metastasis [@B51]. The overexpression of ITGAV had been found in several types of tumors to be related to metastasis and late-stage [@B34],[@B35]. In Koukoulis et al.\'s immunohistochemistry assay, the LADs obtained the most strong staining for ITGAV, while the carcinoids and bronchoalveolar carcinoma (BAC), a subtype of LAD which has no stromal, vascular, or pleural invasion, showed weak staining[@B75],[@B76]. In addition, FYN, a member of Src family kinases, played an important role as a mediator of metastatic progression of disease apart from local tumor growth [@B77]. There were hardly any experiments had been carried out on lung cancer about FYN.

The difference between stage IA and stage IB in TNM staging was only the tumor size. Our pathway analysis showed that Oxidative stress, Glycolysis/Gluconeogenesis and Integrin-mediated cell adhesion pathways were SPRs in stage IB but not in stage IA. Genes and pathways conferring more aggressive proliferation and invasive character might be activated in the preinvasive stages, such as stage IB. The significance of the finding was that the character of stage IB was toward to advanced stages, the early stage of LAD might be stage IA only.

The lung adjuvant cisplatin-based chemotherapy might be effective to stage IB and more advanced stages but not stage IA [@B12]. Cisplatin is believed to form adducts with DNA, inhibiting replication and transcription [@B78]. However, several recent studies have shown that the cytotoxicity of cisplatin may also be related to the cellular defense systems that protect against oxidative stress induced by hydroperoxides in cancer cells. Simons et al. demonstrated that 2-Deoxy-D-Glucose (2DG), an agent for glucose deprivation, combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells [@B79]. The agent also increased the efficacy of Adriamycin and paclitaxel in human osteosarcoma and NSCLC in vivo, according to Maschek et al.\'s assay [@B80].

The products of glucose metabolism, pyruvate (from glycolysis) and NADPH (from the pentose cycle), are believed to play a role in hydroperoxide detoxification[@B81],[@B82]. So, the up-regulation in glucose metabolism in cancer cells might also be necessary to produce more pyruvate to compensate for the increased hydroperoxides. The insignificance of Oxidative stress and the Glycolysis/Gluconeogenesis pathways in stage IA might explain the less benefit with adjuvant chemotherapy. Our pathway analysis result suggested strong connections between Oxidative stress and cisplatin-based adjuvant chemotherapy, as well as the Glycolysis/Gluconeogenesis pathways.

These three pathways revealed the potential molecular mechanisms differences among different stages. Moreover, comparing the stage IA and stage IB, stage IB had more favorable mechanism to have node involvement potential. It emphasized again the importance of tumor size in TNM staging. The insignificant three pathways in stage IA might be used in early stage detection of LAD. Whether the genes in these three pathways might be used for prognosis signature need further investigation.

We noticed that some DEGs were found in the comparison of Normal vs IA and IB, but not found in the comparison of Normal vs IIIA and IIIB. However, DEGs in the comparison of Normal vs IIIA and IIIB were often showed in the comparison of Normal vs IA and IB, which indicated that mechanism of progression to stage III is different from that to stage I. We did not compare the data in stage II due to it is interim stage and few datasets (2 datasets) were involved in the meta-analysis.

We randomly selected 18 genes to verify the meta-analysis result with real-time PCR using LAD cell line Calu-3 and H1299 to mimic the human lung LAD with and without metastasis. Two genes showed opposite regulation tendency in the real-time PCR compared with the meta-analysis result. In the group A, *NT5E* had a fold change of 1.19, and the up-regulation Q value was 0.0000084866 which was only found in the comparison of Normal vs IB; in the group B, *SPP1* was significantly down-regulation in real-time PCR instead of up-regulation in the meta-analysis. The other three genes, *LIMK1*, *VIM* and *HMGA1* were in the same expression tendencies in the two analyses, but showed no significant expression change in real time PCR.

Number of DEGs was dependent on the sample size and the number of datasets combined. When an individual comparison included more datasets, the small sample size of some datasets might not affect the final result if DEGs were integrated from different combinations. However, when few datasets were included, the impact of the small sample size on DEGs might be obvious, such as the comparison Normal vs IIA. It might also be the main reason why the comparison between normal and stage IV revealed no DEGs. The comparison could be made in only one combination (Dataset2 and Dataset4), and the samples of stage IV were both fewer in these datasets. Further analysis should be taken, when more eligible datasets for stage IV are available.

Conclusion
==========

We identified a group of genes, which might associate with the complicated metastasis process in LAD using meta-analysis of different microarray datasets. These genes involved in wider pathways differences among different LAD stages. Among them, the adipogenesis pathway had not been reported to be a SRP in LAD, while the involvement of ID pathway in NSCLC was only reported in the last two years. Most of the genes from the same gene family were found to be up-regulated (or down-regulated). The similar trend of expression of these gene family members suggested coordinate regulation. Importantly, meta-analysis lead to fewer DEGs and produced higher probability of false negatives when integrating datasets with smaller sample size. Cautions should be taken when interpreted the result of meta-analysis with small sample size involved. The insignificant three pathways (Oxidative stress, Glycolysis/Gluconeogenesis and Integrin-mediated cell adhesion pathways) in stage IA might be used in early-stage detection of LAD.
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![A model for meta-analysis of microarrays (Normal vs stage IA). Firstly, 10,000 one-sided random permutation t tests were performed between normal group and stage IA group in each dataset, and generated a series of P values. Secondly, the datasets were assigned to different combinations, such as all four datasets (ABCD). For a given combination, the overlapping genes and their corresponding P values were picked out. Thirdly, the random permutation s test (Formula 1) was calculated in every combination and the significant changed genes (up- or down- regulated in tumors compared with normal tissues) were screened with Q values (Q\<0.1) (Formula 2). Formula 1: S = -2\*log (p1) + -2\*log (p2) + ... + -2\*log (pn). \[p is P(t) value; n is the total number of datasets\]. Formula 2: Q = (P\*n)/i. \[P is P(s) value; n is the total number of genes; i is the index of sorted P (s)\].](ijbsv07p0551g01){#F1}

![Flow diagrams for data analysis. The datasets were assigned into several comparison groups between normal tissues and LADs in different stages. The meta-analysis was performed in each comparison to generate significantly changed genes (see Figure [1](#F1){ref-type="fig"} for details), which were reserved for GO and Pathway analysis. The randomly selected DEGs from Normal vs IA and Normal vs IB were tested in Calu-3 lung adenocarcinoma and WI-38 normal lung cell lines using real-time PCR; DEGs from Normal vs IIIA and Normal vs IIIB were validated with H1299 lung adenocarcinoma and WI-38 cell lines by real-time PCR.](ijbsv07p0551g02){#F2}

###### 

Real-time PCR validations of 18 candidate genes. Bars represent log2 fold changes of the selected genes with differential expression between A) Calu-3 and WI-38, B) H1299 and WI-38. Positive represents up-regulated and negative represents down-regulated in tumor cells compared with normal lung cells. The group A gene *TYRP1*, *DDR1*, *RUNX3*, *GRB7*, *SMARCC1*, *CEACAM1*, *CTGF* showed \>2-fold change in mRNA expression level, which were in consistency with the result of meta-analysis. *NT5E* and *LIMK1* showed no significant change in mRNA expression; the fold changes were 1.19 and 1.1, respectively. The group B gene *MPP1*, *GPX3*, *ACE*, *STAT5A*, *ID3* and *CDKN1C* showed \>2-fold change in mRNA expression level, which were in consistency with the result of meta-analysis. The expression of *VIM* and *HMGA1* had the same up- and down- regulation tendency compared with the meta-analysis result, but showed no significant change in real-time PCR analysis. *SPP1* showed the opposite regulation tendency.
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###### 

Q values of two datasets combinations for 18 genes A) the Q values of stage IIIA from all two datasets combinations for 9 genes in group B. All the Q values from the meta-analyses integrating Dataset2 are on the top part, which indicated datasets with smaller sample size contributed to false negatives; B) the Q values of stage IB from all two datasets combinations for 9 genes in group A.. The Q values for those integrated Dataset2 tend to be on the top part too. Combination integrated Dataset2 were shown as solid. Note that Dataset2 did not contain the genes ACE and STAT5A. The result of stage IA was shown in [Additional file 2](#SM2){ref-type="supplementary-material"}: Supplementary Figure 1.
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###### 

LAD gene expression datasets used in meta-analysis of microarrays

             Author                 Normal   IA   IB   IIA   IIB   IIIA   IIIB   IV   Array type   Plate form        Total clones   Unique clones
  ---------- ---------------------- -------- ---- ---- ----- ----- ------ ------ ---- ------------ ----------------- -------------- ---------------
  Dataset1   Bhattacharjee et al.   17       29   40   4     17    6      3      2    oligo        GPL91             12625          8889
  Dataset2   Garber et al.          5        5    4    1     1     6      0      10   cDNA         GPL2832/GPL2905   24192          9296
  Dataset3   Beer et al.            10       45   23   0     0     15     3      0    oligo        GPL80             7129           5479
  Dataset4   Landi et al.           49       5    17   3     18    9      3      3    oligo        GPL96             22283          12821
  Total                             81       84   84   8     36    36     9      15                                                 

The unique clones are identified with ref sequence ID.

###### 

The selected 18 candidate genes and primer sequence used in real-time PCR

            Gene Symbol   Primer Sequence
  --------- ------------- ---------------------------------
  A group   LIMK1         5\'CCTGCGGAGCCTCAAGAA 3\'
                          5\'GACGATCCCAAAGGAGAACAC 3\'
            TYRP1         5\'TATGATACCCTGGGAACACT 3\'
                          5\'TTCCAAGCACTGAGCGACAT 3\'
            DDR1          5\'GACACTATCCTCATCAACAACCG 3\'
                          5\'CTGGCTTCTCAGGCTCCATAT 3\'
            RUNX3         5\'TGGCAGGCAATGACGAGA 3\'
                          5\'AGTGATGGTCAGGGTGAAACTC 3\'
            GRB7          5\'GCAGGGCTTGGTAGACGG 3\'
                          5\'CCTCCTCCTCGCTCGG 3\'
            SMARCC1       5\'ACCTCCTCCTACTCCTCATTTTA 3\'
                          5\'ACTGGTTTTTCCTTGTTTTTCTC 3\'
            CEACAM1       5\'GGCATTGTGATTGGAGTAGTGG 3\'
                          5\'TTAGGTGGGTCATTGGAGTGG 3\'
            CTGF          5\'CTGCCCTCGCGGCTTAC 3\'
                          5\'GGAGATGCCCATCCCACA 3\'
            NT5E          5\'CCAATGGTGGAGATGGGTT 3\'
                          5\'CGACCTTCAACTGCTGGATAA 3
  B group   MPP1          5\'CTTCTGCGAGATGACCCTCA 3\'
                          5\'CACAGTATTCAATGGATGCGATA 3\'
            GPX3          5\'CTGACGGGCCAGTACATTG 3\'
                          5\'GGTCGGACATACTTGAGGGT 3\'
            SPP1          5\'GGGAGGGCTTGGTTGTCA 3\'
                          5\'AATCACTGCAATTCTCATGGTAGT 3\'
            ACE           5\'CTGCACCGTCACTACGGG 3\'
                          5\'GAAGGGAAGGGCACCACC 3\'
            VIM           5\'ACTTTTCCTCCCTGAACCTGA 3\'
                          5\'TCGTGATGCTGAGAAGTTTCG 3\'
            HMGA1         5\'AGCGAAGTGCCAACACCTAA 3\'
                          5\'TGCCCTCCTCTTCCTCCTT 3\'
            STAT5A        5\'GCCTGTCCGTGTCCTGGT 3\'
                          5\'GTGGGGCTTGTGGTGCTT 3\'
            ID3           5\'GTCCTGACACCTCCAGAACGC 3\'
                          5\'GGATTTGGTGAAGTCAAGTGGG 3\'
            CDKN1C        5\'GCTGCGGTGAGCCAATTT 3\'
                          5\'CGGTTGCTGCTACATGAACG 3\'
  Control   GAPDH         5\'TGAAGGTCGGAGTCAACGG 3\'
                          5\'TGGGTGGAATCATATTGGAACA 3
            18SrRNA       5\'TTGGTGGAGCGATTTGTCTG 3\'
                          5\'ATCTCGGGTGGCTGAACG 3\'

###### 

Datasets, samples and DEGs (Q\<0.1) in the six comparisons

  Comparisons      Datasets   Normal   Tumor   DEGs   Pathways(Z\>1.96)
  ---------------- ---------- -------- ------- ------ -------------------
  Normal vs IA     4          81       84      1004   42
  Normal vs IB     4          81       84      1419   65
  Normal vs IIA    2          66       7       106    4
  Normal vs IIB    2          66       35      718    42
  Normal vs IIIA   4          81       36      928    47
  Normal vs IIIB   3          76       9       321    35

###### 

The regulation of gene family members

  Gene Family                                    Up-regulation                                                                                                                    Down-regulation                                   Proportion
  ---------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ------------
  Histone cluster                                HIST1H1C,HIST1H2AC,HIST1H2AE,HIST1H2AG,HIST1H2BD,HIST1H2BE,HIST1H2BF,HIST1H2BI,HIST1H2BK,HIST1H3H,HIST2H2AA4,HIST2H2BE,HIST4H4                                                     13/0
  Matrix metallopeptidase                        MMP1,MMP9,MMP11,MMP12,MMP13,MMP14,MMP15,MMP17                                                                                                                                      8/0
  Interleukin receptor                                                                                                                                                            IL1R1,IL3RA,IL4R,IL6R,IL7R,IL10RA,IL11RA,IL18R1   0/8
  Minichromosome maintenance complex component   MCM2,MCM3,MCM4,MCM5,MCM6                                                                                                                                                           5/0
  Inhibitor of DNA binding                                                                                                                                                        ID1,ID2,ID3,ID4                                   0/4
  Collagen                                       COL11A1, COL10A1, COL3A1, COL5A2, COL1A2, COL9A3, COL9A2, COL1A1, COL5A1, COL7A1                                                 COL4A3,COL4A5,COL13A1                             10/3
  Integrin                                       ITGAV, ITGB4                                                                                                                     ITGA5,ITGA6,ITGA7,ITGA8, ITGAL, ITGAX,            2/6

###### 

Top 10 GOs derived from the six comparisons and its corresponding Z scores

  GO                                     Normal vs IA   Normal vs IB   Normal vs IIA   Normal vs IIB   Normal vs IIIA   Normal vs IIIB
  -------------------------------------- -------------- -------------- --------------- --------------- ---------------- ----------------
  coreceptor\\soluble ligand activity    5.328          4.434          17.157          6.381           5.551            9.573
  organ development                      7.546          8.741          6.988           7.613           8.211            8.94
  plasma membrane                        10.17          7.824          4.988           8.097           8.055            7.088
  system development                     7.92           7.609          7.15            7.1             7.259            8.943
  multicellular organismal process       7.334          7.096          7.341           6.669           6.952            10.309
  multicellular organismal development   7.058          7.078          7.254           6.515           7.17             8.867
  plasma membrane part                   9.112          7.037          5.561           6.942           7.899            7.065
  developmental process                  7.759          8.469          5.512           7.006           7.218            7.351
  anatomical structure development       7.326          6.911          6.289           6.575           6.769            8.151
  platelet alpha granule                 5.328          4.434          8.52            6.381           5.551            9.573

###### 

Top 26 pathways derived from the six comparisons and its corresponding Z scores.

  Pathway                                       Normal vs IA   Normal vs IB   Normal vs IIA   Normal vs IIB   Normal vs IIIA   Normal vs IIIB   Rank
  --------------------------------------------- -------------- -------------- --------------- --------------- ---------------- ---------------- ------
  Hs_2-Tissues-Internal_Organs                  8.632          6.741          5.424           5.966           5.922            5.062            0
  Hs_Adipogenesis                               3.93           2.968          3.138           3.359           2.775            4.004            0
  Hs_1-Tissue-Blood_and_Lymph                   8.638          6.16           2.583           4.535           6.702            /                1
  Hs_2-Tissues-Blood_and_Lymph                  6.192          5.84           /               4.442           6.166            3.402            1
  Hs_IL-5_NetPath_17                            6.048          6.114          /               5.106           5.178            4.192            1
  Hs_Complement_and_Coagulation_Cascades_KEGG   5.673          4.175          /               4.042           6.004            3.947            1
  Hs_TGF-beta-Receptor_NetPath_7                5.339          5.428          /               3.432           4.383            2.822            1
  Hs_2-Tissues-Endocrine_and_CNS                4.963          3.81           /               3.74            4.653            3.937            1
  Hs_Circadian_Exercise                         4.825          3.027          /               3.572           5.621            4.016            1
  Hs_Peptide_GPCRs                              4.297          2.135          /               2.674           3.802            3.449            1
  Hs_1-Tissue-Internal_Organs                   4.034          2.054          /               2.697           3.124            3.485            1
  Hs_Prostaglandin_synthesis_regulation         3.467          4.481          /               2.554           3.699            3.683            1
  Hs_Statin_Pathway_PharmGKB                    3.244          2.362          /               4.215           3.439            4.179            1
  Hs_IL-3_NetPath_15                            2.775          2.519          /               2.709           2.037            2.427            1
  Hs_Calcium_regulation_in_cardiac_cells        2.701          3.39           /               2.869           2.217            3.311            1
  Hs_Focal_adhesion_KEGG                        2.355          4.011          /               3.331           5.787            3.706            1
  Hs_Eicosanoid_Synthesis                       2.322          2.867          /               2.282           2.491            5.242            1
  Hs_Glycolysis_Gluconeogenesis                 2.088          2.207          /               2.679           3.253            3.688            1
  Hs_Oxidative_Stress                           /              3.168          /               3.948           3.145            2.21             2
  Hs_Glycolysis_and_Gluconeogenesis             /              2.275          /               2.306           3.153            2.833            2
  Hs_Integrin-mediated_cell_adhesion_KEGG       /              2.758          /               2.277           2.687            3.477            2
  Hs_Matrix_Metalloproteinases                  2.982          2.524          /               2.647           1.953            /                2
  Hs_Id_NetPath_5                               2.76           3.26           /               /               2.04             2.376            2
  Hs_Striated_muscle_contraction                2.749          3.122          /               1.986           /                3.968            2
  Hs_IL-7_NetPath_19                            2.25           3.405          /               3.901           4.01             /                2
  Hs_EGFR1_NetPath_4                            2.141          2.625          3.038           /               /                2.714            2

The "/" suggested that the Z score\<=1.96
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